Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07029009 · ClinicalTrials.gov registry record · Phase 2
Liraglutide Treatment in Patients With Maturity-onset Diabetes of the Young (MODY)
A Phase 2 study of Maturity Onset Diabetes of the Young, sponsored by Man.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 50
- Enrollment target
- 1
- Study location
NCT07029009 is a Phase 2 study of Maturity Onset Diabetes of the Young that is actively recruiting participants, run by Man. The registered enrollment target is 50 participants. The trial reports 1 study location across 1 state.
The verdict
NCT07029009, a Phase 2 study of Maturity Onset Diabetes of the Young, is actively recruiting participants, sponsored by Man.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 50 participants
- Enrollment target
- 1
- Study location
Study Summary
The reason for this research study is to better understand the use of liraglutide, a commonly prescribed Type 2 diabetes medication, in patients with a diagnosis of maturity-onset diabetes of the young (MODY). The investigators are interested in better understanding the way that this drug affects the metabolism and hormone levels of a person with MODY. Many people with MODY report having gastrointestinal (GI) issues such as an upset stomach. Investigators also are interested in finding out if this drug will help with GI issues. If liraglutide does help with this symptom of MODY, the investigators want to know why this happens. If this drug is effective for participants, the investigators will use participants cells to make human induced pluripotent stem cell (iPSC). This means that the investigators will use participant cells to create what are called stem cells, which are cells in the body that are able to be told what their job is. Investigators will use these cells to see what happens in gastrointestinal (GI) tract.
Conditions Studied
Interventions
- DRUG Liraglutide
Study Locations (1)
Ohio
- Cincinnati Children's Hospital Medical Center - Cincinnati
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 50 participants |
| Start Date | 2025-05-08 |
| Est. Completion | 2027-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07029009
The ClinicalTrials.gov registry entry for NCT07029009 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 50 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Man, which has 1 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Maturity Onset Diabetes of the Young appearing as the primary indexed condition, and to 1 intervention - of which Liraglutide is the first listed.
NCT07029009 reports 1 study location spanning 1 distinct geographic area - top geographies include Ohio.
Frequently Asked Questions
What is clinical trial NCT07029009 about?
NCT07029009 is a clinical study titled "Liraglutide Treatment in Patients With Maturity-onset Diabetes of the Young (MODY)". The reason for this research study is to better understand the use of liraglutide, a commonly prescribed Type 2 diabetes medication, in patients with a diagnosis of maturity-onset diabetes of the young (MODY). The investigators are interested in better understanding the way that this drug affects t...
What is the current status of trial NCT07029009?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 50 participants. The study started on 2025-05-08. Estimated completion is 2027-01.
What conditions does trial NCT07029009 study?
This clinical trial studies the following conditions: Maturity Onset Diabetes of the Young.
What interventions are being tested in trial NCT07029009?
The interventions under investigation include: Liraglutide (DRUG).
Who is sponsoring clinical trial NCT07029009?
This trial is sponsored by Man, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07029009 being conducted?
This trial has 1 study location across Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.